Ads
related to: atgam treatment for aplastic anemia- FDA-Approved Treatment
Read details on an iron treatment
option. Download the brochure now.
- ID & IDA Symptoms
Review iron deficiency symptoms,
conditions, and treatment options.
- Download Patient Brochure
Review information about this
uniquely formulated therapy.
- See Our Savings Program
Get support and review potential
prescription savings options today.
- Treatment Safety Info
Review safety info and speak to
your doctor about any concerns.
- Enroll To Receive Updates
Sign up to get access to additional
information and updates.
- FDA-Approved Treatment
Search results
Results From The WOW.Com Content Network
Thymoglobulin and Atgam are currently licensed for use in the treatment of renal allograft rejection; Atgam is additionally licensed for use in the treatment of aplastic anemia. Both drugs are used in off-label applications, especially as immunosuppression induction agents before and/or during kidney transplantation.
Aplastic anemia is a rare, noncancerous disorder in which the blood marrow is unable to adequately produce blood cells required for survival. [44] [45] It is estimated that the incidence of aplastic anemia is 0.7–4.1 cases per million people worldwide, with the prevalence between men and women being approximately equal. [46]
It has also been used in the treatment of aplastic anemia. [ 3 ] [ 4 ] [ 5 ] It is less commonly used than the similar anti-thymocyte globulin (ATG), and like ATG it is associated with cytokine release syndrome in the short term and an increased risk of post-transplant lymphoproliferative disorder in the long term.
With isolated reticulocytopenia, the main cause is Parvovirus B19 infection of reticulocytes leading to transient anemia. [2] In patients who rely on frequent red cell regeneration e.g. sickle cell disease, a reticulocytopenia can lead to a severe anemia due to the cessation in red cell production (erythropoiesis), referred to as aplastic ...
Pure red cell aplasia (PRCA) or erythroblastopenia refers to a type of aplastic anemia affecting the precursors to red blood cells but usually not to white blood cells. In PRCA, the bone marrow ceases to produce red blood cells. There are multiple etiologies that can cause PRCA. The condition has been first described by Paul Kaznelson in 1922. [1]
Aplastic anemia patients present with symptoms related to a decrease in hematopoietic cell production in the bone marrow. The onset is gradual, and the first symptom is frequently anemia or bleeding, though a high temperature or infections may be present at the onset. The following are examples of specific manifestations: [12]
Ad
related to: atgam treatment for aplastic anemia